These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15586623)

  • 21. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
    JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
    Francis CW; Davidson BL; Berkowitz SD; Lotke PA; Ginsberg JS; Lieberman JR; Webster AK; Whipple JP; Peters GR; Colwell CW
    Ann Intern Med; 2002 Oct; 137(8):648-55. PubMed ID: 12379064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
    Colwell CW; Berkowitz SD; Lieberman JR; Comp PC; Ginsberg JS; Paiement G; McElhattan J; Roth AW; Francis CW;
    J Bone Joint Surg Am; 2005 Oct; 87(10):2169-77. PubMed ID: 16203879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J; Ingrid J; Tivadar F
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New anticoagulants.
    Weitz JI; Bates SM
    J Thromb Haemost; 2005 Aug; 3(8):1843-53. PubMed ID: 16102051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The direct thrombin inhibitor melagatran/ximelagatran.
    Brighton TA
    Med J Aust; 2004 Oct; 181(8):432-7. PubMed ID: 15487959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J; Kiesewetter H; Jörg I; Harenberg J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
    Mattsson C; Sarich TC; Carlsson SC
    Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L; Boucher M
    Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ximelagatran: the first oral direct thrombin inhibitor.
    Crowther MA; Weitz JI
    Expert Opin Investig Drugs; 2004 Apr; 13(4):403-13. PubMed ID: 15102589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New anticoagulants for the prevention and treatment of venous thromboembolism.
    McRae SJ; Ginsberg JS
    Vasc Health Risk Manag; 2005; 1(1):41-53. PubMed ID: 17319097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
    Agnelli G; Sonaglia F; Becattini C
    Curr Pharm Des; 2005; 11(30):3885-91. PubMed ID: 16305519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
    Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.